Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
企業コードAIMD
会社名Ainos Inc
上場日Aug 08, 1996
最高経営責任者「CEO」Mr. Chun-Hsien Tsai
従業員数44
証券種類Ordinary Share
決算期末Aug 08
本社所在地8880 Rio San Diego Drive, Ste. 800
都市SAN DIEGO
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号92108
電話番号18588692986
ウェブサイトhttps://www.ainos.com/
企業コードAIMD
上場日Aug 08, 1996
最高経営責任者「CEO」Mr. Chun-Hsien Tsai
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし